220 related articles for article (PubMed ID: 36612246)
1. Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects.
Wang X; Yang X; Wang Y; Chen Y; Yang Y; Shang S; Wang W; Wang Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612246
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
[TBL] [Abstract][Full Text] [Related]
3. HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.
Hoerster K; Uhrberg M; Wiek C; Horn PA; Hanenberg H; Heinrichs S
Front Immunol; 2020; 11():586168. PubMed ID: 33584651
[TBL] [Abstract][Full Text] [Related]
4. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease.
Okada S; Muraoka D; Yasui K; Tawara I; Kawamura A; Okamoto S; Mineno J; Seo N; Shiku H; Eguchi S; Ikeda H
Cancer Sci; 2023 Nov; 114(11):4172-4183. PubMed ID: 37675556
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
6. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
7. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
[TBL] [Abstract][Full Text] [Related]
8. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
[TBL] [Abstract][Full Text] [Related]
9. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract][Full Text] [Related]
10. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors.
Oh S; Lee JH; Kwack K; Choi SW
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614472
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N; Panella D; Georgoudaki AM; Liu H; Özkazanc D; Kučerová L; Duru AD; Spanholtz J; Raimo M
J Hematol Oncol; 2022 Nov; 15(1):164. PubMed ID: 36348457
[TBL] [Abstract][Full Text] [Related]
13. Present and Future of Allogeneic Natural Killer Cell Therapy.
Lim O; Jung MY; Hwang YK; Shin EC
Front Immunol; 2015; 6():286. PubMed ID: 26089823
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy.
Lupo KB; Matosevic S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31163679
[TBL] [Abstract][Full Text] [Related]
15. Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma.
van Vliet AA; Georgoudaki AM; Raimo M; de Gruijl TD; Spanholtz J
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572949
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
17. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
18. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
19. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
20. Rapid generation of NY-ESO-1-specific CD4
Kayser S; Boβ C; Feucht J; Witte KE; Scheu A; Bülow HJ; Joachim S; Stevanović S; Schumm M; Rittig SM; Lang P; Röcken M; Handgretinger R; Feuchtinger T
Oncoimmunology; 2015 May; 4(5):e1002723. PubMed ID: 26155389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]